CTKB

MKT CAP:$575M

Cytek Biosciences, Inc.

Market Cap

$575M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$4.57-$0.35 (-7.11%)

Apr 20, 2026

Company Details

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum...

CEO

Wenbin Jiang

IPO Date

Jul 23, 2021

Website

cytekbio.com

Key Metrics TTM

Revenue

$201M

+0.5% YoY

Net Income

-$67M

EPS (Diluted)

-$0.52

Free Cash Flow

-$9M

Revenue / Share

$1.57

Gross Margin

51.8%

Operating Margin

-20.0%

Net Margin

-33.0%

FCF Margin

-4.4%

P/S

2.9x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$201M+0.5%EPS -$0.52

Q4 2025

Feb 26, 2026

$62M+8.1%EPS -$0.34

Q3 2025

Nov 5, 2025

$52M+1.5%EPS -$0.04

Q2 2025

Aug 6, 2025

$46M-2.2%EPS -$0.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 20	$31M	$19M	$8M
Q1 21	$24M	$14M	$1M
Q2 22	$40M	$25M	-$891.0K
Q3 22	$40M	$27M	$1M
Q1 23	$37M	$21M	-$12M
Q2 23	$50M	$28M	-$9M
Q3 23	$48M	$27M	-$6M
Q4 23	$58M	$33M	-$137.0K
Q1 24	$45M	$23M	-$11M
Q2 24	$47M	$25M	-$9M
Q3 24	$52M	$29M	-$4M
Q4 24	$57M	$34M	$3M
Q1 25	$41M	$20M	-$15M
Q2 25	$46M	$24M	-$11M
Q3 25	$52M	$28M	-$9M
Q4 25	$62M	$33M	-$6M

Valuation

Quarter	P/S	P/E
Q4 20	6.2x	29.6x
Q1 21	5.8x	28.2x
Q2 22	4.8x	49.4x
Q3 22	4.2x	84.9x
Q1 23	4.0x	—
Q2 23	3.4x	—
Q3 23	3.3x	—
Q4 23	3.0x	—
Q1 24	2.9x	—
Q2 24	2.9x	—
Q3 24	2.9x	—
Q4 24	2.9x	—
Q1 25	2.9x	—
Q2 25	2.9x	—
Q3 25	2.9x	—
Q4 25	2.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 20	$12M	$11M
Q1 21	$2M	$1M
Q2 22	-$9M	-$11M
Q3 22	-$8M	-$9M
Q1 23	$3M	$2M
Q2 23	-$3M	-$4M
Q3 23	-$4M	-$6M
Q4 23	$10M	$8M
Q1 24	$4M	$3M
Q2 24	$6M	$5M
Q3 24	$13M	$12M
Q4 24	$2M	$1M
Q1 25	-$125.0K	-$976.0K
Q2 25	$108.0K	-$1M
Q3 25	-$4M	-$5M
Q4 25	-$771.0K	-$2M

Capital Expenditures

Quarter	CapEx
Q4 20	$203.0K
Q1 21	$509.0K
Q2 22	$1M
Q3 22	$1M
Q1 23	$505.0K
Q2 23	$1M
Q3 23	$1M
Q4 23	$2M
Q1 24	$622.0K
Q2 24	$1M
Q3 24	$808.0K
Q4 24	$903.0K
Q1 25	$851.0K
Q2 25	$2M
Q3 25	$655.0K
Q4 25	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	+34.9%	+23.8%
Q2 22	+109.9%	+112.1%
Q3 22	+61.3%	+112.8%
Q1 23	+21.1%	+116.6%
Q2 23	+104.7%	+154.2%
Q3 23	+19.5%	+32.6%
Q4 23	+43.9%	+49.2%
Q1 24	+21.0%	+12.9%
Q2 24	-6.2%	-6.2%
Q3 24	+7.3%	+2.4%
Q4 24	-1.3%	-6.6%
Q1 25	-7.6%	+1.5%
Q2 25	-2.2%	+2.0%
Q3 25	+1.5%	+10.3%
Q4 25	+8.1%	+24.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 20	$271.0K	0.9%
Q1 21	$456.0K	1.9%
Q2 22	$0	0.0%
Q3 22	$4M	10.8%
Q1 23	$5M	12.7%
Q2 23	$6M	11.9%
Q3 23	$6M	12.0%
Q4 23	$6M	9.7%
Q1 24	$6M	12.6%
Q2 24	$7M	15.3%
Q3 24	$7M	13.7%
Q4 24	$7M	12.2%
Q1 25	$7M	16.0%
Q2 25	$7M	14.9%
Q3 25	$6M	10.8%
Q4 25	$6M	8.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 20	$4M	$3M	$5M
Q1 21	$5M	$4M	$4M
Q2 22	$8M	$9M	$8M
Q3 22	$9M	$8M	$9M
Q1 23	$10M	$12M	$11M
Q2 23	$12M	$11M	$14M
Q3 23	$11M	$10M	$12M
Q4 23	$11M	$11M	$12M
Q1 24	$10M	$11M	$13M
Q2 24	$10M	$12M	$12M
Q3 24	$10M	$11M	$12M
Q4 24	$10M	$9M	$12M
Q1 25	$10M	$13M	$13M
Q2 25	$9M	$14M	$12M
Q3 25	$9M	$16M	$12M
Q4 25	$9M	$16M	$13M

Revenue Segments

Quarter	Product	Service
Q2 22	$37M	$3M
Q3 22	$36M	$4M
Q1 23	$31M	$6M
Q2 23	$40M	$9M

Revenue by Geography

Quarter	Asia Pacific	Emea	Other	United States
Q2 22	$6M	$9M	$418.0K	$25M
Q3 22	$7M	$10M	$212.0K	$23M
Q1 23	$6M	$10M	$996.0K	$20M
Q2 23	$7M	$9M	$2M	$31M
Q3 23	$7M	$13M	$2M	$27M
Q4 23	$12M	$21M	$2M	$24M
Q1 24	$6M	$15M	$2M	$21M
Q2 24	$9M	$14M	$1M	$22M
Q3 24	$9M	$17M	$979.0K	$24M
Q1 25	$9M	$12M	$2M	$19M
Q2 25	$8M	$12M	$2M	$24M
Q3 25	$11M	$12M	$2M	$27M
Q4 25	$13M	$20M	$4M	$26M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$363M	$0	$363M
Q2 22	$350M	$0	$350M
Q3 22	$342M	$0	$342M
Q4 22	$297M	$45M	$341M
Q1 23	$129M	$170M	$299M
Q2 23	$132M	$167M	$299M
Q3 23	$164M	$124M	$288M
Q4 23	$167M	$95M	$262M
Q1 24	$169M	$101M	$270M
Q2 24	$178M	$99M	$277M
Q3 24	$162M	$116M	$278M
Q4 24	$99M	$179M	$278M
Q1 25	$95M	$170M	$266M
Q2 25	$75M	$187M	$262M
Q3 25	$93M	$168M	$262M
Q4 25	$91M	$171M	$262M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 20	123M	-3.9%	—
Q1 21	127M	+3.2%	+3.2%
Q2 22	134M	+5.9%	+5.0%
Q3 22	139M	+3.2%	+8.4%
Q1 23	135M	-2.3%	+10.1%
Q2 23	136M	+0.3%	+7.1%
Q3 23	136M	+0.2%	+1.3%
Q4 23	131M	-4.0%	-5.8%
Q1 24	131M	+0.2%	-3.4%
Q2 24	131M	+0.4%	-3.3%
Q3 24	133M	+1.0%	-2.5%
Q4 24	129M	-2.7%	-1.2%
Q1 25	128M	-0.7%	-2.0%
Q2 25	127M	-1.1%	-3.4%
Q3 25	128M	+0.5%	-3.9%
Q4 25	128M	+0.5%	-0.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 20	—	—
Q1 21	—	—
Q2 22	$80.0K	502
Q3 22	$80.6K	502
Q1 23	$63.6K	583
Q2 23	$85.2K	583
Q3 23	$82.3K	583
Q4 23	$86.1K	676
Q1 24	$66.4K	676
Q2 24	$69.0K	676
Q3 24	$76.2K	676
Q4 24	$88.7K	648
Q1 25	$64.0K	648
Q2 25	$70.4K	648
Q3 25	$80.7K	648
Q4 25	$88.5K	702

Revenue / Employee